In recent news, Takeda Pharmaceutical Company Limited is gaining traction amongst individual investors, who now make up 52% of the company's shares. This upward trend has sparked queries on whether the stock is undervalued. Solid Q3 performance and improved guidance suggest this might be the case. Nonetheless, some Investors did express concerns after the company's earnings missed analyst forecasts. In other news, the company awarded $13.8 million to U.S. nonprofit partners and introduced a gastrointestinal drug in India, in collaboration with Sun Pharma. Despite the CEO's resignation due to a prolonged drop in shares, Takeda continues to prioritize expansion, particularly in early-stage investments. Share repurchase progress reports have also been released. Morgan Stanley who recently uplifted Takeda's stock rating, hinting at further growth. The company concluded a subsidiary liquidation and merger, and is looking toward a potential turnaround after a 6.19% drop in shares within a month. The company continues to pique the interest of institutional investors, who currently own 48% of shares. Lastly, the company has entered into a promising agreement for Vonoprazan tablets, however, a recent immuno-oncology pact was terminated.
Takeda Pharmaceutical Stocks News Analytics from Mon, 09 Jan 2017 08:00:00 GMT to Wed, 30 Apr 2025 13:32:00 GMT -
Rating 4
- Innovation 3
- Information 5
- Rumor -1
